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Abstract
Background/Aim. Despite years of research in a number
of experimental models the question whether nitric oxide
(NO) and methylene blue (MB) have pro- or anticonvulsant
effects remains to be fully resolved. Methods. In adult
Wistar rats the influence of a nonselective inhibitor of nitric
oxide synthase NG-nitro-L-arginine methyl ester (L-
NAME, 10 Ƭg) on clinical and biochemical effects of MB
(10 Ƭg) given before the intraperitoneally administered
chemical convulsant pentylenetetrazole (PTZ, 80 mg/kg)
was examined. MB and L-NAME were applied intracere-
broventricularly. PTZ application was followed by a 4-
minute observation time, after which rats were sacrificed
and elements of oxido-reductive balance were measured in a
crude mitochondrial fraction of forebrain cortex, hippo-
campus and striatum. Results. Convulsive responses (fore-
limb dystonia – FLD, generalised clonic- and clonic-tonic
convulsions – GCC and GCTC respectively) were observed
in all rats received PTZ, together with significantly de-
creased lipid peroxidation in the forebrain cortex and stria-
tum and increased superoxide dismutase activity in the hip-
pocampus, in comparison to controls (saline treated). It was
registered anticonvulsant effects of L-NAME pretreatment.
However, these effects were insignificant. In the hippocam-
pus of these animals there was decreased lipid peroxidation
(p < 0.01, p < 0.05 vs saline-treated and PTZ-treated rats, re-
spectively) and reverted PTZ-induced increase of superox-
ide dismutase activity. But MB individually pretreatment
significantly decreased the incidence of CTCs and GCCs
(FLD: p = 0.0513), prolonged the convulsive latent time for
FLD, GCTCs and GCCs, in all the examined brain regions
increased lipid peroxidation and decreased the level of su-
peroxide anion. Administration of L-NAME 10 minutes be-
fore MB reverted all MB-evoked clinical and biochemical
effects. Conclusion. Methylene blue applied individually
before PTZ has strong anticonvulsant effects that were
eliminated by L-NAME pretreatment. These effects and
changed biochemical parameters in the brains of animals
treated by L-NAME before MB in comparison to MB-
treated group suggest involvement of NO in MB’s effects in
the animal model of PTZ-evoked convulsions.
Key words:
seizures; nitric oxide; methylene blue;
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Apstrakt
Uvod/Cilj. I pored višegodišnjeg istraživanja na razliÿitim
eksperimentalnim modelima, nije potpuno odgovoreno na
pitanje da li azot-oksid (NO) i metilen plavo (MP) deluju
konvulzivno ili antikonvulzivno. Metode. Na odraslim
pacovima Vistar soja ispitivan je uticaj NG-nitro-L-arginin
metil estra (L-NAME, 10 Ƭg), neselektivnog inhibitora
azot oksid sintaze, na kliniÿke i biohemijske efekte metilen
plavog (MP, 10 Ƭg) datog intracerebroventrikularno pre
hemijskog konvulziva pentilentetrazola (PTZ, 80 mg/kg),
primenjenog intraperitonealno. Pacovi su posmatrani ÿetiri
minuta posle davanja PTZ-a, posle ÿega su žrtvovani i u
nepreÿišýenoj mitohondrijskoj frakciji prednjeg mozga, hi-
pokampusa i strijatuma odreĀivani su parametri oksido-
reduktivne ravnoteže. Rezultati. Posle primene PTZ-a,
konvulzivni odgovor (distonija prednjih nogu – DPN, ge-
neralizovane kloniÿne – GKK i generalizovane kloniÿno-
toniÿne konvulzije – GKTK) bio je ispoljen kod svih ži-
votinja, kao i statistiÿki znaÿajno sniženje lipidne peroksi-
dacije u kori prednjeg mozga i strijatuma, i poveýanje akti-
vnosti superoksid dizmutaze (SOD) u hipokampusu, u po-
reĀenju sa kontrolnom grupom (dobila fiziološki rastvor
NaCl). Registrovani su antikonvulzivni efekti L-NAME
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koji nisu bili statistiÿki znaÿajni. U hipokampusu ovih ži-
votinja bila je snižena lipidna peroksidacija (p < 0,01 u po-
reĀenju sa kontrolnom grupom, p < 0,05 u poreĀenju sa
životinjama koje su dobile PTZ), kao i aktivnost SOD u
poreĀenju sa životinjama koje su dobile PTZ. Samo meti-
len plavo dovelo je do statistiÿki znaÿajnog smanjenja inci-
dencije GKK I GKTK (DPN: p = 0,0513), produžilo je
latentni period DPN, GKK i GKTK, a u svim ispitivanim
strukturama mozga bila je poveýana lipidna peroksidacija i
smanjen nivo superoksidnog anjona. Svi kliniÿki i biohe-
mijski efekti izazvani primenom MP u potpunosti su ods-
tranjeni primenom L-NAME 10 minuta pre davanja MP.
Zakljuÿak. Metilen plavo, dat samostalno pre PTZ, ispo-
ljio je snažne antikonvulzivne efekte. Nestanak ovih efe-
kata i izmenjeni biohemijski parametri u mozgovima paco-
va koji su pre MP dobili L-NAME, sugerišu da je NO uk-
ljuÿen u efekte MP ispoljene na životinjskom modelu kon-
vulzija izazvanih primenom PTZ-a.
Kljuÿne reÿi:
konvulzije; azot, oksid; metilensko plavilo;
pentilentetrazol; pacovi; oksidoredukcija.
Introduction
An accumulated body of evidence supports multiple
physiological as well as pathological roles for nitric oxide
(NO) in its free radical form. Acting both presynaptically and
postsynaptically NO accomplishes its complex participation
in a wide range of physiological and pathophysiological phe-
nomena including regulation of vascular tone, inflammation
and signalling in the central nervous system (CNS) via poly-
synaptic interacting circuits 1, 2.
Nitric oxide is synthesised from L-arginine by nitric
oxide synthases (NOS) in response to N-methyl-D-aspartate
(NMDA) and non-NMDA receptor activation, and it is in-
hibited by a number of NOS inhibitors, among which is NG-
nitro-L-arginine methyl ester (L-NAME). Alternatively, it
can be released from NO donors. Besides hemoglobin, NOS
and other metaloenzymes which are targets for NO binding,
the interaction between NO and heme moiety within the
soluble (cytosolic) form of guanylate cyclase (sCG) has par-
ticular physiological significance. The consequence of NO
binding to sGC is the activation of the latter resulting in an
elevation of cyclic guanosine 3’,5’-monophosphate (cGMP)
and the initiation of a cascade of target cell-specific events 3.
Although much effort has been made to elucidate how NO
interacts and stimulates sGC the precise mechanism is still
unclear to date.
Despite years of research, the role of NO in the patho-
genesis of epilepsy and convulsions still remains controver-
sial. NO can provoke convulsions but also it can exhibit anti-
convulsant effects 4–6. In addition, some convulsive patterns
are NO-independent 7, 8. Such unbalanced reports maybe re-
flected by the use of different experimental conditions, in-
volving not only different animal species and strains, but also
other factors including age, sex, convulsive models, the
form, the route and doses of the applied substances.
During convulsions the concentration of cGMP in-
creases in specific brain regions. Within the first four min-
utes of pentylenetetrazole (PTZ) application, which evokes
generalised clonic convulsions (GCCs) and generalised clo-
nic-tonic convulsions (GCTCs) in almost all mice, increases
in cGMP (3- to 5-fold) were found primarily in the hippo-
campus and cerebral cortex but also (to a lesser extent) in the
cerebellum 9. Within the first minute of PTZ application a
rapid and very high level of cGMP was found in ventilated
and non-ventilated guinea pigs in all the above-mentioned
brain structures and also in the striatum, suggesting that in-
creased cGMP is a pathogenic component of PTZ-evoked
convulsions. The above mentioned brain structures are most
important in convulsions initiation and propagation.
Methylene blue (MB), a highly active redox compound
that readily cycles between oxidised (methylene blue) and
reduced (leukomethylene blue) states, is a blue-coloured or-
ganic dye. Besides in experimental conditions, MB has im-
portance in human clinical practice too, although data about
its effects in humans are not uniform 10, 11.
The effects of MB on cGMP and on NO have already
been documented in several studies. Since MB is a nonselec-
tive and a weak incomplete inhibitor of sGC, this effect of
MB on sGC has been widely studied 12, 13. MB can attenuate
cGMP accumulation by inhibiting NO-stimulated cGC with-
out an effect on the basal cGMP level 14. Masaki and
Kondo 15 intracerebrovetricularly administered MB to rats 30
minutes prior to sacrificing them. In whole brain homogenate
the level of cGMP decreased in a MB dose-dependent man-
ner. MB administration can also decrease the NOS activity
and NO content in certain brain regions and also prevents
experimental seizures 16, 17.
The NO-sGC-cGMP signalling pathway is present in
virtually all cells but sGC is expressed at particularly high
levels within neurons. This pathway is largely influenced by
glutamatergic neurotransmission that is modulated in re-
sponse to PTZ treatment 18.
According to a number of data, as well as to our own
results, it is obvious that elements of oxidative/antioxidative
balance are changed in the brains of rats with convulsive re-
sponse to PTZ and upon L-NAME treatment in such kind of
experimental convulsions 19, 20. Because of these facts but
also due to MB’s ability as well as L-NAME and PTZ to in-
terfere with synthesis/actions of NO, and due to their convul-
sive/anticonvulsive properties, we sought to determine their
influence on both clinical and brain biochemical changes
(parameters of oxidative defence and stress) in a PTZ seizure
model in rats 5–7, 12, 16, 17.
Methods
Animals and surgery
Experiments were performed on 13-week old male
Wistar rats housed in a temperature-controlled room (23 ±
2ºC) with 11-hour light/13-hour dark cycles with free access
Volumen 69, Broj 6 VOJNOSANITETSKI PREGLED Strana 483
Jelenkoviý A, et al. Vojnosanit Pregl 2012; 69(6): 481–487.
to food and water. Experiments were conducted within a pe-
riod of two weeks always between the hours of 9:00 am and
2:00 pm. Animals were randomly assigned to different drug
treatment regimes. All protocols for handling the rats were
approved by the local ethical committee for the use of ex-
perimental animals (Military Medical Academy, Belgrade,
Serbia).
For intracerebroventricular (icv) application of drugs a
polyethylene cannula was stereotaxically implanted into the
left lateral ventricle (coordinates: 1.3 mm behind the bregma,
1.8 mm left from the midline suture, 3.7 mm ventral from the
durra 21) under sodium pentobarbital intraperitoneally (ip)
anaesthesia (45 mg/kg body weight, Vetanarcol®, Werfft-
Chemie, Vienna). The cannula was fixed to the skull with
dental cement and two jeweller screws. The postoperative
recovery period lasted six days before experiments were
continued.
Treatments
Rats were divided into five groups (Figure 1; in each
group there were 7–8 rats). PTZ (Sigma Chemical Co., St
Louis) was used as a chemoconvulsant. It was applied ip in a
single dose of 80 mg/kg body weight. The control group re-
ceived sterile isotonic saline icv twice: 30 minutes and 20
minutes before ip application of the same solution. Another
group of rats also received sterile isotonic saline icv twice:
30 and 20 minutes before ip application of PTZ (PTZ-treated
group). The third group received 10 Pg NG-nitro-L-arginine
methyl ester (L-NAME, Sigma Chemical Co.) icv 30 minutes
before PTZ. Ten minutes after the L-NAME injection the
rats also received sterile isotonic saline icv.
MB (10 Pg) was administered icv to another two groups
of rats 10 minutes after sterile isotonic saline (icv) or L-
NAME (10 Pg, icv) 15. Twenty minutes after MB (30 minutes
after sterile isotonic saline/L-NAME treatment), both groups
of rats received PTZ. All drugs were dissolved in sterile iso-
tonic saline. Volume of ip and icv applied solutions were 1
mL/kg body weight and 10 PL, respectively.
Behavioural evaluation
Immediately after PTZ administration the rats were
placed individually in transparent perspex cages. The time of
observation following PTZ injection was limited to 4-min.
During that time convulsive responses were monitored and
were graded according to the following scale: fore limb
dystonia (FLD), generalised clonic seizures (clonus of the
whole body with a loss of righting reflex, GCCs) and gener-
alised clonic-tonic convulsions with tonic hind limb exten-
sion (GCTCs). The appearance (incidence) and the time to
onset of every convulsive pattern were registered. If the rats
did not exhibit convulsive responses, a latent time of 240 sec
was assigned.
Biochemical parameters
All the rats were sacrificed by decapitation 4 min after
PTZ administration. Their heads were immediately frozen in
liquid nitrogen and stored at -70ºC.
For biochemical analysis the forebrain cortex, striatum
and hippocampus from the contralateral hemisphere relative to
cannula insertion were dissected on ice, homogenized in ice-
cold buffer, centrifuged and sonicated. Biochemical parame-
ters were determined spectrophotometrically in the crude mi-
tochondrial fraction according to the method of Gurd et al. 22.
The assay for the superoxide radical is based on the
reduction of nitrobluetetrazolium (Merck) in an alkaline,
nitrogen-saturated buffer with absorbance monitoring at
515 nm 23.
Total superoxide dismutase (SOD) activity was
measured as the inhibition of epinephrine auto-oxidation
(Sigma Chemical Co.) in sodium carbonate buffer (Serva)
containing 0.1 mM EDTA (Sigma Chemical Co.) at 480
nm 24.
Lipid peroxidation was measured as a function of ma-
londialdehyde (MDA) production at 533 nm 25.
The incidence of convulsive patterns was expressed as
the percentage of convulsing rats of the total number of rats
in a group and was analysed using Kolmogorov-Smirnov
test. The latent time of convulsions was calculated in seconds
and expressed as the mean ± standard deviation (SD) and
was analysed using the Kruskal-Wallis test. Biochemical pa-
rameters were expressed as the mean ± SD and were ana-
lysed using the ANOVA, followed by Tuckey test. Differ-
ences between experimental groups were considered signifi-
cant when p < 0.05.
0-10-20-30
TIME (minutes)
NaCl (icv) NaCl (icv)
NaCl (icv) NaCl (icv)
L-NAME(icv)
NaCl (icv)
NaCl (icv)
L-NAME(icv)
MB (icv)
MB (icv)
NaCl (ip)
PTZ (ip)
PTZ (ip)
PTZ (ip)
PTZ (ip)
Group 1
Group 2
Group 3
Group 4
Group 5
Fig. 1 – Protocol of treatments (n = 7–8 Wistar rats in each group)
NaCl – 0.9% saline; PTZ – pentylenetetrazole; L-NAME – NG-nitro-L-arginine methyl ester; MB – methylene blue;
ip – intraperitoneally; icv – intracerebroventricularly
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Results
Behavioural effects
In the control group of rats (sterile isotonic saline
treatment, icv and ip) no convulsions were observed. In con-
trast, convulsive responses were observed in all PTZ-treated
rats (Figure 2).
Fig. 2 – Influence of NG-nitro-L-arginine methyl ester (L-
NAME, 10 Pg) and methylene blue (MB, 10 Pg) on
pentylenetetrazole (PTZ, 80 mg/kg) – evoked convulsions in
Wistar rats (n = 7–8)
p < 0.05, p < 0.01 is the level of significance when compared with the
corresponding PTZ (*, **) and MB + PTZ-treated rats (Ƈ, ƇƇ; Kolmogorov-
Smirnov test). PTZ was applied intraperitoneally, 0.9% NaCl, L-NAME and
MB intracerebroventricularly; FLD – forelimb dystonia; GCC – generalised
clonic convulsions; GCTC – generalised clonic-tonic convulsions
Pretreatment with L-NAME led to some anticonvulsant,
however insignificant effects on PTZ-induced convulsions.
MB pretreatment was very effective against PTZ-
evoked convulsions. GCTCs were completely prevented (p <
0.01, compared to the PTZ-treated group). GCCs appeared
only in 25% of animals (p < 0.01). FLD was apparent in 50%
of the rats (p = 0.0513).
When L-NAME was administered before MB, the anti-
convulsant effects of MB were lost, in particular GCTCs and
GCCs; their incidence increased from 0 to 83%; (p < 0.01),
and from 25 to 83% (p < 0.05), respectively. In addition the
incidence of FLD was doubled, from 50 to 100% (p = 0.0513).
The latent time of PTZ-evoked convulsions was not
influenced by L-NAME pretreatment (Table 1). MB very
strongly influenced the latent time of all three convulsive
patterns (p < 0.01 for FLD and GCTC, p < 0.05 for GCC,
compared with the PTZ-treated group and groups pre-
treated with L-NAME). But MB’s ability to extend the la-
tent time of PTZ-induced convolutions was completely
blocked by L-NAME.
Biochemical effects
In the PTZ-treated group of rats decreased lipid peroxi-
dation in the forebrain cortex and striatum compared with the
control group was found (p < 0.05 and p < 0.01, respec-
tively) (Figure 3). In addition, increased SOD activity in the
hippocampus compared with the control group was noted (p
< 0.05) (Figure 4).
Fig. 3 – Influence of NG-nitro-L-arginine methyl ester (L-
NAME 10 Pg) and methylene blue (MB, 10 Pg) on lipid
peroxidation in the brain of Wistar rats (n = 7–8) treated
with pentylenetetrazole (PTZ, 80 mg/kg)
p < 0.05, 0.01 is the level of significance when compared with the
corresponding values (mean ± SD) of 0.9% NaCl (*, **) and PTZ-treated rats
(Ƈ, ƇƇ; ANOVA test). PTZ was applied intraperitoneally, NaCl
intraperitoneally and intracerebroventricularly, L-NAME and MB
intracerebroventricularly
Fig. 4 – Influence of NG-nitro-L-arginine methyl ester (L-
NAME 10 Pg) and methylene blue (MB, 10 Pg) on the
superoxide dismutase (SOD) activity in the brain of Wistar
rats (n = 7–8) treated with pentylenetetrazole (PTZ (80
mg/kg)
p < 0.05, 0.01 is the level of significance when compared with the
corresponding values (mean ± SD) of 0.9% NaCl (*, **) and PTZ-treated
rats (Ƈ, ƇƇ; ANOVA). PTZ was applied intraperitoneally, NaCl
intraperitoneally and intracerebroventricularly, L-NAME and MB
intracerebroventricularly
Table 1
Time to onset of pentylenetetrazole (PTZ, 80 mg/kg) – evoked convulsions in Wistar rats (n = 7–8)
Latent time (seconds)Treatment
L-NAME and MB (Pg) FLD GCC GCTC
NaCl + PTZ 49.5 ± 11.3ƇƇ 118.6 ± 25.8Ƈ 131.7 ± 35.6ƇƇ
L-NAME (10) + PTZ 57.7 ± 11.9ƇƇ 125 ± 68.3Ƈ 128 ± 67ƇƇ
MB (10) + PTZ 159.2 ±  88.7** 213.3 ± 65.3* 240 ± 0**
L-NAME (10) + MB (10) + PTZ 53.3 ±  8.8ƇƇ 123.5 ± 70.4Ƈ 126.7 ± 70ƇƇ
p < 0.05, 0.01 is the level of significance when compared with the corresponding PTZ (*, **) and MB+PTZ treatments (Ƈ, ƇƇ; Kruskal-
Wallis test). Values are expressed as means ± SD. In the case without convulsive response, the latent time was assigned as 240 seconds.
PTZ was applied intraperitoneally, 0.9% NaCl, L-NAME and MB intracerebroventricularly
FLD – forelimb dystonia; GCC – generalised clonic convulsions; GCTC – generalised clonic-tonic convulsions; L-NAME – NG-nitro-
Larginine methyl ester; MB – methylen blue
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Treatment with L-NAME prior to PTZ administration
decreased lipid peroxidation in the hippocampus (p < 0.01,
compared with the control group; p < 0.05, compared with
the PTZ-treated group) (Figure 3). SOD activity was de-
creased in the forebrain cortex (p < 0.05, compared with the
control group) (Figure 4). Superoxide anion content of the
hippocampus was also decreased (p < 0.05, compared with
the control group) (Figure 5).
Fig. 5 – Influence of NG-nitro-L-arginine methyl ester (L-
NAME 10 Pg) and methylene blue (MB, 10 Pg) on the
superoxide anion content of the brain of Wistar rats (n = 7–
8) treated with pentylenetetrazole (PTZ, 80 mg/kg).
p < 0.05, 0.01 is the level of significance when compared with the
corresponding values (mean ± SD) of 0.9% NaCl (*, **) ) and PTZ-treated
rats (Ƈ, ƇƇ; ANOVA). PTZ was applied intraperitoneally, NaCl
intraperitoneally and intracerebroventricularly, L-NAME and MB
intracerebroventricularly
MB administered before PTZ resulted in increased lipid
peroxidation compared with the control group (p < 0.05 in
the forebrain cortex, p < 0.01 both in the striatum and hippo-
campus) and compared with the PTZ-treated group of rats (p
< 0.01 for all brain regions) (Figure 3).
The level of superoxide anion was decreased in the
MB+PTZ treated group of rats compared with both the con-
trol and PTZ-treated groups (p < 0.01 in all brain regions)
(Figure 5).
Pretreatment with L-NAME reverted the MB+PTZ-
induced increase in lipid peroxidation (Figure 3) and de-
crease in superoxide anion (Figure 5) in all brain regions
back to the control values, except in the forebrain cortex
where the superoxide content was increased, while SOD ac-
tivity was decreased (p < 0.05 in comparison with the control
and PTZ-treated groups of rats, and the control group, re-
spectively).
Discussion
We found that both L-NAME and MB affected PTZ-
evoked convulsions (insignificant and almost com-
pletely/completely prevented, respectively). However, co-
administration of L-NAME and MB did not result in an ad-
ditive/synergistic effects. Instead the effects (clinical and
biochemical) of MB were severely abrogated by L-NAME.
The convulsant effects of PTZ are quite complex and
are not yet completely understood. Reduced Ȗ-aminobutyric
(GABA) activity (GABA suppresses NOS), and enhanced
excitatory amino acids release/transmission is believed to be
the underlying mechanism 26, 27. Thus, PTZ’s effects on both
the GABA-ergic and glutamatergic system lead to overpro-
duction of NO and potentiation of sGC activity.
NO preferentially reacts with other radicals despite being
a free radical itself. Its reactivity with biological molecules is
low but it readily reacts with the hydroxyl radical 28. In this
way it can act as an antioxidant by scavenging free radicals
thereby inhibiting lipid peroxidation. Chiueh 29 proposed at
least four mechanisms by which NO acts as an antioxidant, in-
cluding inhibition of lipid peroxidation. Thus, within the first
few minutes of PTZ administration when cGMP production is
rapidly increased 9, which is an indirect measure of NO pro-
duction, a defence reaction against PTZ’s toxic effects (via the
antioxidative activity of NO) may take place. Under very
strong production of NO and at later times this antioxidative
defence is overcome and lipid peroxidation ensues, as de-
scribed by a number of studies. For example, Patsoukis et
al. 30, 31 found that the intensity of lipid peroxidation was in-
creased in the mouse hippocampus and the striatum 15 min
after PTZ was applied ip at a dose of 60 mg/kg. Furthermore,
increased lipid peroxidation was within control values 30 min
and 24 h post PTZ administration. However, lipid peroxidation
was not increased in the mouse cerebral cortex in each moni-
toring time 32. A lower dose of PTZ (40 mg/kg) did not in any
way influence lipid peroxidation, meaning that lipid peroxi-
datrion is PTZ dose- and time- dependent.
In the research of Bashkatova et al. 33 PTZ (120 mg/kg
administered subcutaneously) caused convulsions in all ani-
mals within 2–3 minutes. Moreover, one hour later the level
of NO was increased 5-fold and lipid peroxidation 2-fold in
the frontal cortex. Despite the fact that PTZ was used as a
chemoconvulsant in both our and the above-mentioned
studies, to some degree different results concerning lipid
peroxidation are most likely explainable due to different ex-
perimental procedures.
The anticonvulsant effects of MB described in our
studies are in accordance with those of Furian et al. 17. In ad-
dition to MB’s ability to increase the latency of methylmalo-
nate-induced convulsions in adult male Wistar rats, abroga-
tion of the methylmalonate-induced striatal NO level eleva-
tion was also observed. Furthermore, in the case of catalepsy
induction Echeverry et al. 34 demonstrated similar effects of
L-NAME and MB, both applied icv. Also, the level of NO
products was decreased in the striatum.
However, discrepancies between our results and the re-
sults obtained by Deutsch et al. 35, who did not record the
anticonvulsant effects of MB in electrically precipitated tonic
hind limb extension in mice, could be explained by the use of
different experimental models of convulsions, routes of drug
administration, time points and dose of MB application,
since pharmacokinetics and organ distribution of MB de-
pends on the way of its application 36.
Apart from inhibition of sGC, MB has several other
nonspecific effects on NO including inhibition of NOS. In
cultured endothelial cells Shimizu et al. 37 found that MB,
which is known to inactivate iron-containing enzymes, reacts
with the heme moiety of NOS. Vallo et al. 16 found similar
effects on hippocampal brain NOS activity in vivo. Further-
Strana 486 VOJNOSANITETSKI PREGLED Volumen 69, Broj 6
Jelenkoviý A, et al. Vojnosanit Pregl 2012; 69(6): 481–487.
more, MB-mediated inhibition of hippocampal NOS was
dose-dependent and the degree of inhibition was similar to
that obtained with an unselective NOS inhibitor N-G-nitro-
L-arginine (L-NNA). In comparison with sGC inhibition,
MB-mediated NOS inhibition appeared more potent 12. The
susceptibility of different NOS isoforms to MB remains un-
clear. Because of NOS inhibition by MB, in our research it
was expected that L-NAME, a competitive non-selective
NOS inhibitor, enhances MB’s anticonvulsant effects. How-
ever, the opposite was apparent: MB’s anti-convulsant ef-
fects were reverted back to control values. In other words,
combined pretreatment with L-NAME and MB exerted
deleterious effects on MB-preventable PTZ-evoked convul-
sions. It is difficult to propose the reason for the obtained
events. In addition to nitrergic system a number of other ef-
fects of both substances have to be taken into consideration
before any conclusion, such as their influence on cholinergic,
dopaminergic, serotoninergic and other transmissions that
are important in the pathogenesis of convulsions 38.
Despite much more evidence pointing towards its anti-
oxidant effects, MB can also be prooxidative causing singlet
oxygen and superoxide formation, weak peroxide generation
and direct glutathione oxidation 39. Inactivation of NO by su-
peroxide is ranked as one of the most rapid nonenzymatic re-
actions in biology. In other words one of MB effect could be
related to the removal of NO already present. The chemical
reaction between NO and superoxide, which could be gener-
ated in the presence of MB, may lead to the formation of
peroxynitrite anion. The latter is a source of the hydroxyl
radical which can intensify lipid peroxidation 40. In our pre-
vious study it was found increased NO leveles in the hippo-
campus, forebrain cortex, striatum and some other brains
structures within 30 minutes of PTZ application in the PTZ-
evoked convulsions in rats 41. Therefore, abovementioned ef-
fects of PTZ are in agreement with our observation regarding
increased lipid peroxidation and a decreased level of super-
oxide anion in all the examined brain structures isolated from
rats pre-treated with MB. Reestablishing level of lipid per-
oxidation in all brain regions and superoxide anion (except in
the forebrain cortex) without increased SOD activity when
L-NAME was coadministered with MB coincide with the
suggested explanation of increased lipid peroxidation upon
MB treatment ie it  could indicate decreased interaction be-
tween NO and superoxide anion. However, increased lipid
peroxidation that was associated with anticonvulsant effects
of MB is undesired for any antiepileptic drug and substance
and needs scientific evidence reliable of benefit/risk ratio
with the aim to study whether benefits of such treatments
(anticonvulsant effects) overwhelm risks of their potential
harmful effects (increased lipid peroxidation).
A cascade of prooxidative events associated with MB
pretreatment was not at all disrupt by coadministration of L-
NAME. That was demonstrated in increased level of super-
oxide anion in the forebrain cortex. It could be the result of
L-NAME effects on SOD activity, which was decreased in
this structure when L-NAME was individually applied be-
fore PTZ. Thus, L-NAME did not only prevent anticonvul-
sant and lipid peroxidation effects of MB, but also it made
conditions for forebrain cortex oxidative damage. In other
words, all three structures in which most of the complex
events of epileptic seizures are generated were very sensitive
and prone to PTZ, MB and L-NAME influence.
In our PTZ-mediated convulsing rat model it was reg-
istered very early and rapid events (within the first 4 minutes
after PTZ application): MB, when applied individually, pre-
vented convulsive responses, especially GCTCs and GCCs;
modulation of the NO system by MB in the settings of PTZ-
induced convulsions may elicit anticonvulsant effects, but
only if MB was applied on its own, not in combination with
L-NAME, indicating that NO plays important role into anti-
convulsant effects of MB under applied conditions; convul-
sive responses to PTZ was associated with a decreased
and/or unchanged level of lipid peroxidation in the forebrain
cortex, striatum and hippocampus. In contrast, anticonvul-
sant effects of MB coincide with increased lipid peroxida-
tion. These clinical and biochemical effects of MB were
abandon by L-NAME treatment.
Conclusion
MB’s strong anticonvulsant effects in PTZ-evoked con-
vulsions, especially against generalised clonic and clonic-
tonic convulsions, and changes of the examined biochemical
parameters in brain structures, as well as prevention of all
these effects by L-NAME applied before MB could be partly
the result of the nitrergic system modulation. Our results
have far reaching therapeutic implications, ie translation into
clinical practice benefits, particularly the anticonvulsant ef-
fects of MB. Future investigations will hopefully shed some
light on the intricacies of MB’s effects.
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